Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder
NCT00397098
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
257
Enrollment
INDUSTRY
Sponsor class
Stopped
reprioritization of indications
Conditions
Anxiety Disorders
Interventions
DRUG:
SR58611A
Sponsor
Sanofi